Access to Healthcare Strategy: Availability

Boehringer Ingelheim has one of the strongest medical Research & Development pipelines globally for areas of unmet need in developing countries. But the journey of a medicine from the factory to patients and communities in poorer and more remote parts of the world is often long and difficult. Regulatory hurdles, lack of infrastructure, and the presence of falsified medicines mean that some life-saving treatments do not reach the people who need them. 

Through our Access to Healthcare Strategy, we want to ensure that our compounds are readily and responsibly available. The following areas give an impression on how we prioritize approaches and initiatives that we believe provide the most effective solutions to some of today’s challenges to access: 

• Research & Development Investment for Unmet Need
• Supply Chain Optimization
• Human Pharma patents approach in developing countries

Some examples of what we are currently doing: 

• Research & Development collaboration with Peking University, China: A multifaceted partnership with one of the world’s leading life-science research institutes to jointly advance early scientific innovation across a range of areas of high medical need.
• OpnMe.com: An Open Innovation portal providing access to the Boehringer Ingelheim molecule library for sharing and collaboration to benefit drug discovery.
• Policy on Access to Healthcare and Property Patent Rights in Developing Countries